Advertisement

Distribution of a Boronated Porphyrin in Murine Tumors

  • S. B. Kahl
  • B. H. Laster
  • M.-S. Koo
  • L. S. Warkentien
  • R. G. Fairchild
Part of the Basic Life Sciences book series (BLSC, volume 50)

Abstract

Boron neutron capture therapy (BNCT) as an effective therapeutic technique in the treatment of glioblastoma multiforme, a malignant and lethal brain disease, is largely dependent upon the availability of boronated compounds which demonstrate high tumor-to-normal tissue concentration ratios. The 10boron-thermal neutron reaction [10B(n,α)7Li] can successfully induce tumor cell reproductive death provided that the 10B atoms are distributed within or around the cell so that the resultant α-particle will traverse the cell nucleus at least to some extent. It is generally thought that 20–30 μg of 10B/g of tumor could achieve therapeutic results when irradiated with a thermal neutron fluence of 5×1012 n/cm2.1,7

Keywords

Tumor Uptake Boron Concentration Boron Neutron Capture Therapy Boron Distribution Thermal Neutron Fluence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R. G. Fairchild and V. P. Bond, Current status of 10B-neutron capture therapy: enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: a theoretical evaluation, Int. J. Radiat. Oncol. Biol. 11: 831 (1985).CrossRefGoogle Scholar
  2. 2.
    “Neutron Capture Therapy” H. Hatanaka, ed., Nishimura Co. Ltd., Japan (1985).Google Scholar
  3. 3.
    D. N. Slatkin, P. Micca, A. Forman, D. Gabel, L. Wielopolski, and R. G. Fairchild, Boron uptake in melanomas, cerebrum and blood from Na2B12H11SH and Na4B24H22S2 administered to mice, Biochem.Pharmacol. 35: 1771 (1986).Google Scholar
  4. 4.
    D. N. Slatkin, D. D. Joel, R. G. Fairchild, P. L. Micca, M. M. Nawrocky, B. H. Laster, J. A. Coderre, G. C. Finkel, and W. H. Sweet, Distributions of sulfhydryl borane monomer and dimer in rodents and monomer in humans: boron neutron capture therapy of melanoma and glioma in boronated rodents. (This Symposium).Google Scholar
  5. 5.
    T. J. Dougherty, D. H. Boyle, K. R. Weishaupt, B. A. Henderson, W.R. Potter, D. A. Bellmier, and K. E. Wityk, Photoradiation therapy - clinical and drug advances, in: “Porphyrin Photosensitization”, D. Kessel and T. J. Doughtery, ed., Plenum Publishing Corp., NY (1983).Google Scholar
  6. 6.
    R. G. Fairchild, D. Gabel, B. H. Laster, D. Greenberg, W. Kiszenick, and P. L. Micca, Microanalytical techniques for boron analysis using the ’°B(n,a)7Li reaction, Med. Phys. 13: 50 (1986).Google Scholar
  7. 7.
    R. G. Fairchild, J. A. Kalef-Ezra, S. Fiarman, and F. Wheeler, Physics aspects of boron neutron capture therapy: Epithermal neutron beam optimization, Proc. ANS Topical Meeting, Jackson Hole, WY, Sept. 19-21, Vol. II, 423 - 433 (1988).Google Scholar
  8. 8.
    R. G. Fairchild, et al. Recent developments in neutron capture therapy, Proc. Workshop on Fast Neutron Therapy, Neuherberg and Munich, Oct,. 16-17, 1987 (in press).Google Scholar
  9. 9.
    R. G. Fairchild, D. Gabel, M. Hillman, and K. Watts, The distribution of exogenous porphyrins in vivo, and implications for neutron capture therapy. Proc. 1st Intl. Symp. on Neutron Capture Therapy, Oct. 12-13, 1983. BNL Report No. 51730, pp. 266 - 275, 1984.Google Scholar
  10. 10.
    B. H. Laster, S. B. Kahl, E. A. Poepnoe, C. Gordon, J. Kalef-Ezra, and R. G. Fairchild, Survival assays with a boronated porphyrin as measured with hamster V-79 cells in culture. (This Symposium).Google Scholar
  11. 11.
    B. H. Laster, E. A. Popenoe, and R. G. Fairchild, Uptake of IdUrd in murine melanoma following multiple-day intravenous infusions, Proc. Workshop on Photon Activation Therapy, BNL Report No. 51997, pp. 17 - 14, 1985.Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • S. B. Kahl
    • 1
  • B. H. Laster
    • 1
    • 2
  • M.-S. Koo
    • 1
  • L. S. Warkentien
    • 1
    • 2
  • R. G. Fairchild
    • 1
    • 2
  1. 1.School of Pharmacy Department of Pharmaceutical ChemistryUniversity of CaliforniaSan FranciscoUSA
  2. 2.Medical DepartmentBrookhaven National LaboratoryUptonUSA

Personalised recommendations